IL162150A0 - Use of anastrozole for the treatment of post-menopausal women having early breast cancer - Google Patents

Use of anastrozole for the treatment of post-menopausal women having early breast cancer

Info

Publication number
IL162150A0
IL162150A0 IL16215002A IL16215002A IL162150A0 IL 162150 A0 IL162150 A0 IL 162150A0 IL 16215002 A IL16215002 A IL 16215002A IL 16215002 A IL16215002 A IL 16215002A IL 162150 A0 IL162150 A0 IL 162150A0
Authority
IL
Israel
Prior art keywords
breast cancer
anastrozole
post
early breast
treatment
Prior art date
Application number
IL16215002A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9927290&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL162150(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL162150A0 publication Critical patent/IL162150A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Chemical Treatment Of Metals (AREA)
IL16215002A 2001-12-10 2002-12-06 Use of anastrozole for the treatment of post-menopausal women having early breast cancer IL162150A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0129457.8A GB0129457D0 (en) 2001-12-10 2001-12-10 Method of treatment
PCT/GB2002/005554 WO2003053438A1 (en) 2001-12-10 2002-12-06 Use of anastrozole for the treatment of post-menopausal women having early breast cancer

Publications (1)

Publication Number Publication Date
IL162150A0 true IL162150A0 (en) 2005-11-20

Family

ID=9927290

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16215002A IL162150A0 (en) 2001-12-10 2002-12-06 Use of anastrozole for the treatment of post-menopausal women having early breast cancer

Country Status (29)

Country Link
US (1) US20050165081A1 (es)
EP (2) EP1455781B1 (es)
JP (2) JP5335173B2 (es)
KR (1) KR100858946B1 (es)
CN (1) CN100408036C (es)
AT (1) ATE406160T1 (es)
AU (1) AU2002347371B2 (es)
BR (1) BR0214798A (es)
CA (1) CA2468965C (es)
CO (1) CO5590926A2 (es)
CY (1) CY1108462T1 (es)
DE (1) DE60228616D1 (es)
DK (1) DK1455781T3 (es)
ES (1) ES2303811T3 (es)
GB (1) GB0129457D0 (es)
HK (1) HK1069335A1 (es)
HU (1) HUP0402023A3 (es)
IL (1) IL162150A0 (es)
IS (1) IS7300A (es)
MX (1) MXPA04005394A (es)
NO (1) NO20042912L (es)
NZ (1) NZ533106A (es)
PL (1) PL369411A1 (es)
PT (1) PT1455781E (es)
RU (1) RU2320339C2 (es)
SI (1) SI1455781T1 (es)
UA (1) UA79443C2 (es)
WO (1) WO2003053438A1 (es)
ZA (1) ZA200404260B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0129457D0 (en) * 2001-12-10 2002-01-30 Astrazeneca Ab Method of treatment
US8436029B2 (en) * 2004-03-19 2013-05-07 Transform Pharmaceuticals, Inc. Pharmaceutical forms, and methods of making and using the same
WO2005117864A1 (en) * 2004-05-28 2005-12-15 Astrazeneca Ab Combination product comprising anastrozole and a dual prenyl transferase inhibitor
CN100337625C (zh) * 2004-08-30 2007-09-19 鲁南制药集团股份有限公司 阿那曲唑的分散片剂型
CN1304054C (zh) * 2004-12-29 2007-03-14 山东蓝金生物工程有限公司 一种缓慢释放的抗癌药物组合物
GB0517674D0 (en) * 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
GB0517673D0 (en) * 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
WO2011130381A1 (en) * 2010-04-13 2011-10-20 Estrocept Diagnostics, Inc. Diagnostic assays for breast cancer treatment and progression
US10201549B2 (en) 2013-06-14 2019-02-12 Professional Compounding Centers Of America (Pcca) Testosterone combined with anastrozole injection solutions
CN103450099B (zh) * 2013-09-06 2015-03-25 杭州华东医药集团新药研究院有限公司 阿那曲唑及其一水合物的新晶型、制备和用途
RU2548722C1 (ru) * 2013-12-06 2015-04-20 Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" Противоопухолевое лекарственное средство пролонгированного действия на основе противоопухолевого препарата, ингибитора синтеза эстрогенов - анастрозола
DE102014005513B4 (de) 2014-04-15 2018-03-15 Sanoxsys Gmbh Mittel zur Prävention und Therapie von Tumorerkrankungen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8714013D0 (en) * 1987-06-16 1987-07-22 Ici Plc (substituted-aralkyl)heterocyclic compounds
AR034142A1 (es) * 2000-09-08 2004-02-04 Sloan Kettering Inst Cancer Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
GB0129457D0 (en) * 2001-12-10 2002-01-30 Astrazeneca Ab Method of treatment

Also Published As

Publication number Publication date
EP1997492A1 (en) 2008-12-03
ES2303811T1 (es) 2008-09-01
KR20040066886A (ko) 2004-07-27
IS7300A (is) 2004-06-04
HUP0402023A2 (hu) 2005-01-28
BR0214798A (pt) 2004-10-19
CA2468965A1 (en) 2003-07-03
DK1455781T3 (da) 2008-11-24
CO5590926A2 (es) 2005-12-30
CA2468965C (en) 2011-08-30
AU2002347371A1 (en) 2003-07-09
ATE406160T1 (de) 2008-09-15
RU2320339C2 (ru) 2008-03-27
PL369411A1 (en) 2005-04-18
RU2004121162A (ru) 2005-05-20
JP2011016828A (ja) 2011-01-27
MXPA04005394A (es) 2005-04-19
GB0129457D0 (en) 2002-01-30
CY1108462T1 (el) 2014-04-09
ES2303811T3 (es) 2009-02-01
CN100408036C (zh) 2008-08-06
JP2005516021A (ja) 2005-06-02
EP1455781A1 (en) 2004-09-15
US20050165081A1 (en) 2005-07-28
JP5335173B2 (ja) 2013-11-06
CN1630519A (zh) 2005-06-22
NO20042912L (no) 2004-08-25
UA79443C2 (en) 2007-06-25
EP1455781B1 (en) 2008-08-27
SI1455781T1 (sl) 2008-12-31
ZA200404260B (en) 2005-10-26
DE60228616D1 (de) 2008-10-09
NZ533106A (en) 2008-02-29
WO2003053438A1 (en) 2003-07-03
HK1069335A1 (en) 2005-05-20
PT1455781E (pt) 2008-11-03
KR100858946B1 (ko) 2008-09-17
AU2002347371B2 (en) 2007-05-10
HUP0402023A3 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
HK1069335A1 (en) Use of anastrozole for the treatment of post-menopausal women having early breast cancer
MY127290A (en) New use of flibanserin
HK1061354A1 (en) Synthesis of 4-amino-thalidomide enantiomers
TR200201442T2 (tr) Ağrı hafifletme, kemik kanseri terapisi ve kemik yüzeyinin sağlıklı tutulması için kireçlenmiş hedef dokulara yönelik radyum-223 hazırlanması ve kullanımı.
HUP0500424A3 (en) Combination therapy for the treatment of cancer
HK1068261A1 (en) Combinations comprisinga selective cyclooxygenase-2 inhibitor
HUP0301460A2 (hu) Antiprogresztinek használata hormonfüggő betegségek megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállításához
AU2003217397A8 (en) Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer
MXPA04004306A (es) Uso de antagonistas del receptor de endotelina para el tratamiento de enfermedades tumorales.
WO2006037485A3 (en) Methods and kits for the prediction of therapeutic success and recurrence free survival in cancer therapy
BR0311146A (pt) Uso de tibolona e de modulador de receptor de estrogênio seletivo, e, método e kit para o tratamento de um sintoma relacionado com a deficiência de estrogênio em um paciente do sexo feminino
HK1053424A1 (en) The use of exemestane for the preparation of a medicament for the first-line treatment of breast cancer
AU2002313726A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
SV2002000179A (es) Proceso para la preparacion de un compuesto para reducir el riesgo del cancer ref.x-13527-el
AU2002253899A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
RS16804A (en) Use of 4-pyridylmethylphthalazines for cancer treatment
AU2002365104A8 (en) Method for the diagnosis of breast cancer diseases, associated peptides and the uses thereof
徐兵河 et al. THE CLINICAL COURSE AND TREATMENT RESULTS OF LUNG METASTASES FROM BREAST CANCER
TW527918U (en) Medical chest strap dedicated for breast cancer patient
GB0110908D0 (en) Proreins, genes and their use for diagnosis and treatment of breast cancer
WO2000050022A3 (en) Treatment regimen for hormone-sensitive cancers
EP1385497A4 (en) METHOD FOR PREVENTING OR TREATING BREAST CANCER, PROSTATE AND / OR COLUMN OF UTERUS USING N, N-DIMETHYLGLYCIN
GB0118387D0 (en) Proteins,genes and their use for diagnosis and treatment of breast cancer
NZ516564A (en) Cancer therapy
ZA200108257B (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use.